Strategic Agreement with Emtora Biosciences Propels Biodexa’s Oncology Pipeline Forward with Potential to Transform Treatment Landscape
Biodexa Pharmaceuticals PLC (BDRX) has made a significant leap in the advancement of treatments for Familial Adenomatous Polyposis (FAP) with its exclusive license agreement for eRapa™ from Rapamycin Holdings Inc., operating as Emtora Biosciences. This strategic move positions Biodexa at the forefront of FAP treatment development, offering new hope to the estimated 100,000 individuals afflicted with this rare genetic disease in the U.S. and Europe.
The agreement grants Biodexa worldwide rights to eRapa™, a Phase 3 ready asset, along with $17 million in non-dilutive grant funding to support pivotal clinical trials. With the potential to delay or prevent surgical interventions for FAP patients, eRapa™ represents a promising breakthrough in addressing an unmet medical need in the treatment landscape.
Stephen Stamp, CEO and CFO of Biodexa, emphasized the transformative impact of acquiring a Phase 3 ready asset supported by substantial grant funding, underscoring the added value for stakeholders. The partnership with Emtora Biosciences, which has demonstrated excellence in advancing eRapa™ through Phase 2 trials, signifies a collaborative effort to bring innovative therapies to patients in need.
Stephen Dufilho, Executive Chairman of Emtora Biosciences, expressed gratitude for the decade-long effort to advance eRapa™ to this pivotal moment, highlighting the contributions of scientists, clinicians, investors, and biotech executives. The transaction with Biodexa marks a significant milestone in the journey to bring eRapa™ to patients, offering hope for improved treatment outcomes and quality of life for individuals affected by FAP.
Find original press release:Here
You might like this article:Alphabet Surpasses Expectations with Stellar First-Quarter Performance
